These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 26708016)
1. Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells. Sawada T; Watanabe M; Fujimura Y; Yagishita S; Shimoyama T; Maeda Y; Kanda S; Yunokawa M; Tamura K; Tamura T; Minami H; Koh Y; Koizumi F Cancer Sci; 2016 Mar; 107(3):307-14. PubMed ID: 26708016 [TBL] [Abstract][Full Text] [Related]
2. Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. Watanabe M; Kenmotsu H; Ko R; Wakuda K; Ono A; Imai H; Taira T; Naito T; Murakami H; Abe M; Endo M; Nakajima T; Koh Y; Takahashi T Cancer Sci; 2018 Aug; 109(8):2539-2548. PubMed ID: 29900633 [TBL] [Abstract][Full Text] [Related]
3. Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases. van Bussel MTJ; Pluim D; Milojkovic Kerklaan B; Bol M; Sikorska K; Linders DTC; van den Broek D; Beijnen JH; Schellens JHM; Brandsma D Neurology; 2020 Feb; 94(5):e521-e528. PubMed ID: 31907288 [TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Pestrin M; Salvianti F; Galardi F; De Luca F; Turner N; Malorni L; Pazzagli M; Di Leo A; Pinzani P Mol Oncol; 2015 Apr; 9(4):749-57. PubMed ID: 25539732 [TBL] [Abstract][Full Text] [Related]
5. Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer. Gasch C; Oldopp T; Mauermann O; Gorges TM; Andreas A; Coith C; Müller V; Fehm T; Janni W; Pantel K; Riethdorf S Mol Oncol; 2016 Oct; 10(8):1330-43. PubMed ID: 27491860 [TBL] [Abstract][Full Text] [Related]
6. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Schneck H; Blassl C; Meier-Stiegen F; Neves RP; Janni W; Fehm T; Neubauer H Mol Oncol; 2013 Oct; 7(5):976-86. PubMed ID: 23895914 [TBL] [Abstract][Full Text] [Related]
7. Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer. Neves RP; Raba K; Schmidt O; Honisch E; Meier-Stiegen F; Behrens B; Möhlendick B; Fehm T; Neubauer H; Klein CA; Polzer B; Sproll C; Fischer JC; Niederacher D; Stoecklein NH Clin Chem; 2014 Oct; 60(10):1290-7. PubMed ID: 25267515 [TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer. Sawada T; Araki J; Yamashita T; Masubuchi M; Chiyoda T; Yunokawa M; Hoshi K; Tao S; Yamamura S; Yatsushiro S; Abe K; Kataoka M; Shimoyama T; Maeda Y; Kuroi K; Tamura K; Sawazumi T; Minami H; Suda Y; Koizumi F EBioMedicine; 2016 Sep; 11():173-182. PubMed ID: 27495793 [TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Gasch C; Bauernhofer T; Pichler M; Langer-Freitag S; Reeh M; Seifert AM; Mauermann O; Izbicki JR; Pantel K; Riethdorf S Clin Chem; 2013 Jan; 59(1):252-60. PubMed ID: 23136247 [TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer. Markou A; Farkona S; Schiza C; Efstathiou T; Kounelis S; Malamos N; Georgoulias V; Lianidou E Clin Cancer Res; 2014 Nov; 20(22):5823-34. PubMed ID: 25398847 [TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors. Cui S; Ni Y; Zhao Y; Li Z; Xiong L; Liu J; Liang X; Jiang L Lung Cancer; 2019 Jun; 132():45-53. PubMed ID: 31097093 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982 [TBL] [Abstract][Full Text] [Related]
13. EpCAM-independent capture of circulating tumor cells with a 'universal CTC-chip'. Chikaishi Y; Yoneda K; Ohnaga T; Tanaka F Oncol Rep; 2017 Jan; 37(1):77-82. PubMed ID: 27840987 [TBL] [Abstract][Full Text] [Related]
14. Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma. Yoneda K; Kuwata T; Chikaishi Y; Mori M; Kanayama M; Takenaka M; Oka S; Hirai A; Imanishi N; Kuroda K; Ichiki Y; Ohnaga T; Tanaka F Cancer Sci; 2019 Feb; 110(2):726-733. PubMed ID: 30499156 [TBL] [Abstract][Full Text] [Related]
15. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation. Frithiof H; Welinder C; Larsson AM; Rydén L; Aaltonen K J Transl Med; 2015 Apr; 13():126. PubMed ID: 25896421 [TBL] [Abstract][Full Text] [Related]
16. Enumeration, characterization, and collection of intact circulating tumor cells by cross contamination-free flow cytometry. Takao M; Takeda K Cytometry A; 2011 Feb; 79(2):107-17. PubMed ID: 21246706 [TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer. Zhang Y; Liu M; Yang H; Wang J; Liu H; Li X; Li J; Xu J; Li X Neoplasma; 2014; 61(4):461-7. PubMed ID: 25027743 [TBL] [Abstract][Full Text] [Related]